ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Early sedation-related adverse events with the cenobamate-clobazam combination in drug-resistant epilepsy: real-world preliminary observations.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCenobamate is increasingly used as adjunctive treatment in adults with drug-resistant focal epilepsy. In clinical practice, the combination with clobazam is common and sedation-related adverse events (SRAEs) have been reported.
methodsWe conducted a retrospective single-centre analysis of adult patients with drug-resistant epilepsy treated with cenobamate between January and September 2025. Clinical data, concomitant antiseizure medications, and adverse events were collected during routine follow-up. SRAEs occurring within three months of cenobamate initiation were classified as early. Particular attention was paid to patients receiving concomitant clobazam. Pharmacogenetic data were available as part of routine clinical assessment.
resultsSRAEs were observed more frequently among patients receiving the cenobamate-clobazam combination and were mostly reported within the first three months of treatment. Among affected patients, clobazam doses ranged between 10 and 30 mg/day. When pharmacogenetic data were considered, a higher proportion of SRAEs was observed among intermediate CYP2C19 metabolizers compared with other phenotypes, although the sample size was limited.
conclusionsIn this real-world cohort, early SRAEs were observed in a subset of patients receiving the cenobamate-clobazam combination, particularly among individuals with reduced CYP2C19 metabolic activity. Further prospective studies are needed to clarify the pharmacokinetic and pharmacogenetic contributions to these adverse events.
Indexed as
Identifiers
42014614What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.